Understanding how immune cells affect treatment resistance in pancreatic cancer
Intratumoral Metabolic Crosstalk Promotes Therapeutic Resistance in Pancreatic Cancer
['FUNDING_R37'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10885696
This study is looking at how certain immune cells in pancreatic cancer might make it harder for the chemotherapy drug gemcitabine to work, and it hopes to find ways to change these cells to help improve treatment for patients.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10885696 on ClinicalTrials.gov |
What this research studies
This research investigates the role of tumor-associated macrophages (TAMs) in pancreatic cancer, particularly how they contribute to resistance against the chemotherapy drug gemcitabine. By examining the metabolic interactions between these immune cells and cancer cells, the study aims to uncover mechanisms that prevent effective drug delivery. The researchers will utilize advanced techniques to analyze how these immune cells produce and release deoxycytidine, a substance that hampers the effectiveness of gemcitabine. Additionally, they will explore potential strategies to reprogram TAMs to improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who are undergoing treatment with gemcitabine.
Not a fit: Patients with pancreatic cancer who are not receiving gemcitabine or those with advanced disease stages may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for pancreatic cancer, enhancing the effectiveness of existing chemotherapy.
How similar studies have performed: Previous research has shown that targeting the tumor microenvironment can enhance the effectiveness of chemotherapy in other cancer types, suggesting potential for success in this approach.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LYSSIOTIS, COSTAS ANDREAS — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: LYSSIOTIS, COSTAS ANDREAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, cancer cell, Cancer Etiology, Cancers